Safe use of long-acting β-agonists: what have we learnt?

Bibliography

• Bateman ED, Hurd SS, Barnes PJ, Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78
   PubMed Web of Science ®Google Scholar
• Prenner BM. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Curr Opinion Pulm Med 2008;14:57-63
   PubMed Web of Science ®Google Scholar
• WebMD, 111 Eighth Ave, New York, NY 10011, 30 Dec, 2010
   Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71
   PubMed Web of Science ®Google Scholar
• Sears MR, Taylor DR. The beta 2-agonist controversy: observations, explanations, and relationship to asthma epidemiology. Drug Safety 1994;11:259-83
   PubMed Web of Science ®Google Scholar
• Crane J, Pearce N, Flatt A, Prescribed fenoterol and death from asthma in New Zealand, 1981-83. Case-control study. Lancet 1989;1:918-22
   Google Scholar
• Grainger J, Woodman K, Pearce N, Prescribed fenoterol and death from asthma in New Zealand, 1981 – 7: a further case-control study. Thorax 1991;46:105-11
   PubMed Web of Science ®Google Scholar
• Sears MR, Taylor DR, Print CG, Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6
   PubMed Web of Science ®Google Scholar
• Taylor DR, Sears MR, Herbison GP, Regular inhaled beta agonist in asthma: effect on exacerbations and lung function. Thorax 1993;48:134-8
   PubMed Web of Science ®Google Scholar
• Sears MR. Epidemiological trends in asthma. Can Respir J 1996;3:261-8
   Google Scholar
• Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993;306:1034-7
   PubMed Web of Science ®Google Scholar
• Mann M, Chowdhury B, Sullivan E, Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003;124:70-4
   PubMed Web of Science ®Google Scholar
• Bensch G, Lapidus RJ, Levine BE, A randomized, 12-week, placebo-controlled double-blind study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001;86:19-27
   PubMed Web of Science ®Google Scholar
• Bensch G, Berger WE, Blokhin BM, One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180-90
   PubMed Web of Science ®Google Scholar
• Wolfe J, LaForce C, Friedman B, Formoterol 24 mcg bid, and serious asthma exacerbations. Chest 2006;129:27-38
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, The salmeterol multicenter asthma research trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• McCoy L, Redelings M, Sorvillo F, Simon P. A multiple cause-of-death analysis of asthma mortality in the United States, 1990 – 2001. J Asthma 2005;42:757-63
   PubMed Web of Science ®Google Scholar
• Moorman JE, Rudd RA, Johnson CA, National surveillance for asthma–United States, 1980-2004. MMWR Surveill Summ 2007;56:1-54
   PubMedGoogle Scholar
• Wechsler ME, Kunselman SJ, Chinchilli VM, Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomized, placebo-controlled, crossover trial. Lancet 2009;374:1754-64
   PubMed Web of Science ®Google Scholar
• Murphy S, Roberts R. ‘Black-box’ 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006;117:34-9
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006;144:904-12
   PubMed Web of Science ®Google Scholar
• Hagan P. Four in five asthma deaths may be due to long-acting beta agonists. Br Med J 2006;332:1467
   PubMed Web of Science ®Google Scholar
• Ernst P, McIvor A, Ducharme FM, Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med 2006;145:692-4
   PubMed Web of Science ®Google Scholar
• Nelson HS, Dorinsky PM. Safety of long-acting beta-agonists. Ann Intern Med 2006;145:706
   PubMedGoogle Scholar
• Jaeschke R, O'Byrne PM, Mezja F, The safety of long-acting beta2-agonists among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Am J Respir Crit Care Med 2008;178:1009-16
   PubMed Web of Science ®Google Scholar
• Jaeschke R, O'Byrne PM, Nair P, The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Pol Arch Med Wewn 2008;118:627-35
   PubMedGoogle Scholar
• Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez J. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Therap 2009;22:9-19
   PubMed Web of Science ®Google Scholar
• Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33:21-32
   PubMed Web of Science ®Google Scholar
• Bateman E, Nelson H, Bousquet J, Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008;149:33-42
   PubMed Web of Science ®Google Scholar
• Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events (Review). Cochrane Database Syst Rev 2008;(3):CD006363
   Google Scholar
• Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events (Review). Cochrane Database Syst Rev. 2008;((4)CD006923-
   Google Scholar
• Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events (Review). Cochrane Database Syst Rev. 2009;((3)CD006922-
   Google Scholar
• Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee, December 10-11, 2008. Available from: http://www.fda.gov/ohrms/dockets/ac/cder08.html#PulmonaryAllergy
   Google Scholar
• Lemanske RF, Sorkness CA, Mauger EA, Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. A randomized controlled trial. JAMA 2001;285:2594-603
   PubMed Web of Science ®Google Scholar
• McIvor RA, Pizzichini E, Turner MO, Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30
   PubMed Web of Science ®Google Scholar
• Thomas M, von Ziegenweidt J, Lee AJ, Price D. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. J Allergy Clin Immunol 2009;123:116-21
   PubMed Web of Science ®Google Scholar
• Vaessen-Verberne AAPH, van den Berg NJ, van Nierop JC, Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010;182:1221-7
   PubMed Web of Science ®Google Scholar
• Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and meta-analysis. Chest 2009;136:145-54
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010;123:322-8
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Church NL, Gillman SA, Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 1999;36:703-15
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Barnes PJ, Rodriguez-Roison R, Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7
   PubMed Web of Science ®Google Scholar
• Ind PW, Dal Negro R, Colman NC, Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003;97:555-62
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Bisgaard H, Godard PP, Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Le Roux P, Bjamer D, Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 2006;130:1733-43
   PubMed Web of Science ®Google Scholar
• Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists – the influence of values. N Engl J Med 2009;360:1592-5
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180:817-22
   PubMed Web of Science ®Google Scholar
• Hasford J, Uricher J, Tauscher M, Persistence with asthma treatment in low in Germany especially for controller medication – a population based study of 483 051 patients. Allergy 2010;65:347-54
   PubMed Web of Science ®Google Scholar
• Williams LK, Peterson EL, Wells K, A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol 2010;126:225-31
   PubMed Web of Science ®Google Scholar
• Stanford RH, Gilsenan AW, Ziemiecki R, Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the asthma control characteristics and prevalence survey studies (ACCESS). J Asthma 2010;47:257-62
   PubMed Web of Science ®Google Scholar
• Lemanske RF, Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 2010;126:449-52
   PubMed Web of Science ®Google Scholar
• Reddel HK, Gibson PG, Peters MJ, Down-titration from high-dose combination therapy in asthma: removal of long-acting beta2-agonist. Respir Med 2010;104:1110-20
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Delea TE, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc 2010;31:203-10
   PubMed Web of Science ®Google Scholar
• Beasley R, Martinez FD, Hackshaw A, Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J 2009;33:3-5
   PubMed Web of Science ®Google Scholar
• Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009;360:1671-2
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl C-G, Postma DS, Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997;337:1405-11
   PubMed Web of Science ®Google Scholar
• Sears MR. Safety of long-acting beta-agonists. Are new data really required? Chest 2009;136:604-7
   PubMed Web of Science ®Google Scholar
• Weatherall M, Wijesinghe M, Perrin K, Meta-analysis of the risks of mortality with salmeterol and the effects of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43
   PubMed Web of Science ®Google Scholar
• Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009;103:1960-68
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757-69
   PubMed Web of Science ®Google Scholar
• Nair P, Hargreave FE. Measuring bronchitis in airway diseases: clinical implementation and application. Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 2010;138(Suppl):38S-43S
   Google Scholar
• Cowan DC, Cowan JO, Palmay R, Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90
   PubMed Web of Science ®Google Scholar
• Schleich FN, Seidel L, Sele J, Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥ 3% in a cohort of unselected patients with asthma. Thorax 2010;65:1039-44
   PubMed Web of Science ®Google Scholar
• Taylor DR, Cowan DC. Assessing airway inflammation. Thorax 2010;65:1031-2
   PubMed Web of Science ®Google Scholar
• Nair P, Kjarsgaard M, Armstrong S, Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. J Allergy Clin Immunol 2010;126:404-6
   PubMedGoogle Scholar
• van Veen IH, ten Brinke A, Gauw SA, Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009;124:615-17
   PubMed Web of Science ®Google Scholar
• Al-Samri MT, Benedetti A, Prefontaine D, Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol 2010;125:1161-3
   PubMed Web of Science ®Google Scholar